The reiteration of an Outperform rating and a maintained price target of $35 by a reputable analyst like Luca Issi from RBC Capital is likely to instill confidence among investors and could lead to a positive short-term impact on Verve Therapeutics' stock price. Analyst ratings, especially from well-regarded financial institutions, often influence investor sentiment and can lead to price movements.